Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21838458 | 1.00 | RAB9A (0.49) | RAB9ANPC1PKMMAOAMAOB | |
| SCHEMBL21838460 | 1.00 | RAB9A (0.49) | RAB9ANPC1PKMMAOAMAOB | |
| SCHEMBL30220799 | 1.00 | RAB9A (0.49) | RAB9ANPC1PKMMAOAMAOB | |
| SCHEMBL745117 | 1.00 | RAB9A (0.49) | RAB9ANPC1PKMMAOAMAOB | |
| SCHEMBL21097694 | 0.80 | HSP90AA1 (0.55) | RAB9ANPC1PKML3MBTL1MEN1 | |
| SCHEMBL11327597 | 0.80 | HSP90AA1 (0.55) | RAB9ANPC1PKML3MBTL1MEN1 | |
| SCHEMBL11332710 | 0.80 | HSP90AA1 (0.55) | RAB9ANPC1PKML3MBTL1MEN1 | |
| SCHEMBL8924537 | 0.77 | RAB9A (0.50) | RAB9ANPC1PKMMAOAMAOB | |
| SCHEMBL2619262 | 0.77 | RAB9A (0.50) | RAB9ANPC1PKMMAOAMAOB | |
| SCHEMBL745118 | 0.77 | RAB9A (0.50) | RAB9ANPC1PKMMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140038305-A1 | ARTICLES AND METHODS FOR THE DETECTION AND QUANTIFICATION OF ULTRAVIOLET LIGHT | PROPPER MANUFACTURING COMPANY, INC. (US) | 2014-02-06 | — | — | US | claimed |
| US-20260130966-A1 | NOVEL THERAPEUTICS FOR PARASITIC INFECTION | UNIV SOUTH FLORIDA (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4289830-B1 | NLRP3 INFLAMMASOME SMALL-MOLECULE INHIBITOR FOR TREATMENT OF ALZHEIMER'S DISEASE | UNIV AJOU IND ACADEMIC COOP FOUND (KR) | 2026-04-08 | — | — | EP | disclosed |
| US-12558354-B2 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-02-24 | — | — | US | disclosed |
| US-20260021127-A1 | pH REGULATING HYDROGELS THAT NEUTRALIZE CANCER CELL ENVIRONMENT ACIDOSIS AND INCREASE CHEMOTHERAPY EFFICACY | UNIV BROWN (US) | 2026-01-22 | — | — | US | disclosed |
| US-12409187-B2 | PH regulating hydrogels that neutralize cancer cell environment acidosis and increase chemotherapy efficacy | BROWN UNIVERSITY (US) | 2025-09-09 | — | — | US | disclosed |
| US-20240358746-A1 | METHOD OF OBTAINING STABLE SUSPENSIONS OF HETEROCRYSTALS OF TITANIUM DIOXIDE OR PARTICLES OF SILICON DIOXIDE AND STABLE SUSPENSIONS OBTAINED BY THIS METHOD FOR INITIATION OF ACTIVE FORM OF OXYGEN IN BODY AT USE IN MEDICAL FORMS | KURKAYEV ABDULA (HU) | 2024-10-31 | — | — | US | disclosed |
| US-20240309045-A1 | NLRP3 INFLAMMASOME INHIBITORY PEPTIDE FOR TREATMENT OF INFLAMMATORY DISEASES | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2024-09-19 | — | — | US | disclosed |
| US-20240132458-A1 | NLRP3 INFLAMMASOME SMALL-MOLECULE INHIBITOR FOR TREATMENT OF ALZHEIMER'S DISEASE | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2024-04-25 | — | — | US | disclosed |
| WO-2024081969-A1 | NOVEL THERAPEUTICS FOR PARASITIC INFECTION | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-1653988-A2 | LEUKOCYTE INTERNALIZED PEPTIDE-DRUG CONJUGATES | THE UNIVERSITY OF KANSAS (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20050202399-A1 | Method of assay by oxidation-reduction reaction with formazan | ARKRAY, INC. (JP) | 2005-09-15 | — | — | US | disclosed |
| EP-1515143-A1 | METHOD OF ASSAY BY OXIDATION-REDUCTION REACTION WITH FORMAZAN | ARKRAY, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2005002516-A2 | LEUKOCYTE INTERNALIZED PEPTIDE-DRUG CONJUGATES | UNIVERSITY OF KANSAS (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20040037775-A1 | Leukocyte internalized peptide-drug conjugates | KANSAS, UNIVERSITY OF | 2004-02-26 | — | — | US | disclosed |
| US-20030220250-A1 | Angiopoietin-1 in the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-11-27 | — | — | US | disclosed |
| WO-2003068165-A2 | ANGIOPOIETIN-1 IN THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-1999006040-A9 | METHOD OF TREATING DISEASE USING A TOCOTRIENOL AND ALPHA-LIPOIC ACID OR DERIVATIVES OR AN ESTER THEREOF | BERRY CHRISTOPHER J (TH) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999006040-A1 | METHOD OF TREATING DISEASE USING A TOCOTRIENOL AND ALPHA-LIPOIC ACID OR DERIVATIVES OR AN ESTER THEREOF | BERRY CHRISTOPHER J (TH) | 1999-02-11 | — | — | WO | disclosed |
| WO-1996013160-A1 | USE OF UROKINASE-TYPE PLASMINOGEN ACTIVATORS TO INHIBIT HIV INFECTIVITY | NEW ENGLAND DEACONESS HOSPITAL (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558354-B2 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | TNF, TNFRSF1A, TNFRSF9 | RAB9A 2163/4885NPC1 2482/4885PKM 4748/4885 |
| US-20260130966-A1 | NOVEL THERAPEUTICS FOR PARASITIC INFECTION | SLC10A1, SLC10A2, ABCB11 | RAB9A 631/4885NPC1 200/4885PKM 481/4885 |
| US-20240132458-A1 | NLRP3 INFLAMMASOME SMALL-MOLECULE INHIBITOR FOR TREATMENT OF ALZHEIMER'S DISEASE | NLRP3, NLRP1, BACE1 | RAB9A 1796/4885NPC1 337/4885PKM 4442/4885 |
| US-20040037775-A1 | Leukocyte internalized peptide-drug conjugates | CD47, TAP1, CD74 | RAB9A 1029/4885NPC1 433/4885PKM 4366/4885 |
| US-20260021127-A1 | pH REGULATING HYDROGELS THAT NEUTRALIZE CANCER CELL ENVIRONMENT ACIDOSIS AND INCREASE CHEMOTHERAPY EFFICACY | FIBP, CD44, COL14A1 | RAB9A 1531/4885NPC1 4209/4885PKM 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.